Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic
-
Published:2023-04
Issue:2
Volume:21
Page:273-277
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Stecca Carlos E.ORCID,
Jiang Di MariaORCID,
Veitch Zachary,
Hotte Sebastian JORCID,
Alimohamed Nimira,
Wood Lori,
Sridhar Srikala S.
Reference17 articles.
1. Canadian Cancer Statistics: A 2018 Special Report on cancer incidence by stage,2018
2. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941;Huggins;J Urol,2002
3. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015
4. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial;Fizazi;Lancet Oncol,2019
5. Given R,et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study;Chi;J Clin Oncol.,2021
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献